SCHEMBL14907005

SCHEMBL14907005

O=C(N/N=C/c1cc(Cl)ccc1O)c1cc(O)c(O)c(O)c1

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM1A O60341 4/20 0.76
MEN1 O00255 6/20 0.72
KMT2A Q03164 6/20 0.72
KDM4E B2RXH2 5/20 0.72
RAB9A P51151 3/20 0.72
HTT P42858 3/20 0.72
NPC1 O15118 3/20 0.72
LMNA P02545 2/20 0.72
SMN1; SMN2 Q16637 2/20 0.72
MITF O75030 2/20 0.72
L3MBTL1 Q9Y468 2/20 0.72
PSMD14 O00487 1/20 0.72
POLB P06746 1/20 0.72
MMP2 P08253 1/20 0.72
BLM P54132 1/20 0.72
GPR174 Q9BXC1 1/20 0.72
KLF5 Q13887 1/20 0.66
PIK3CG P48736 1/20 0.62
MAPT P10636 1/20 0.62
TP53 P04637 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14906912 0.89 KDM1A (0.65) KDM1AMEN1KMT2AKDM4ERAB9A
SCHEMBL14906893 0.89 KDM1A (0.80) KDM1AMEN1KMT2AKDM4ERAB9A
SCHEMBL6568344 0.89 KDM1A (0.89) KDM1AMEN1KMT2AKDM4ERAB9A
SCHEMBL683818 0.89 KDM1A (0.89) KDM1AMEN1KMT2AKDM4ERAB9A
SCHEMBL6568342 0.89 KDM1A (0.89) KDM1AMEN1KMT2AKDM4ERAB9A
SCHEMBL14907000 0.88 RAB9A (0.64) KDM1AMEN1KMT2AKDM4ERAB9A
SCHEMBL20588146 0.86 KMT2A (0.81) KDM1AMEN1KMT2AKDM4ERAB9A
SCHEMBL20587606 0.86 KDM1A (0.72) KDM1AMEN1KMT2AKDM4ERAB9A
SCHEMBL20588144 0.86 KMT2A (0.81) KDM1AMEN1KMT2AKDM4ERAB9A
SCHEMBL20587607 0.86 KDM1A (0.72) KDM1AMEN1KMT2AKDM4ERAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9873661-B2 Small molecule malarial Aldolase-TRAP enhancers and glideosome inhibitors NEW YORK UNIVERSITY (US) 2018-01-23 US disclosed
US-20140275088-A1 SMALL MOLECULE MALARIAL ALDOLASE-TRAP ENHANCERS AND GLIDEOSOME INHIBITORS THE JOHNS HOPKINS UNIVERSITY 2014-09-18 US disclosed
WO-2013063243-A1 SMALL MOLECULE MALARIAL ALDOLASE-TRAP ENHANCERS AND GLIDEOSOME INHIBITORS NEW YORK UNIVERSITY (US) 2013-05-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140275088-A1 SMALL MOLECULE MALARIAL ALDOLASE-TRAP ENHANCERS AND GLIDEOSOME INHIBITORS ALDOA, DERA, TALDO1 KDM1A 247/4885MEN1 1882/4885KMT2A 929/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.